Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: A UK and Ireland multicentre study  by Shah, Emily et al.
Seizure 34 (2016) 1–5Clinical experience with adjunctive perampanel in adult patients with
uncontrolled epilepsy: A UK and Ireland multicentre study
Emily Shah a,1,*, Markus Reuber b, Peter Goulding c, Cora Flynn d, Norman Delanty d,
Steven Kemp a
aDepartment of Clinical and Health Psychology, St James’s University Hospital, Leeds, LS9 7TF, United Kingdom
bDepartment of Neurology, Royal Hallamshire Hospital, Shefﬁeld, S10 2JF, United Kingdom
cDepartment of Neurology, Leeds General Inﬁrmary, Leeds, LS1 3EX, United Kingdom
dDepartment of Neurology, Beaumont Hospital, Dublin, Dublin 9, United Kingdom
A R T I C L E I N F O
Article history:
Received 27 May 2015
Received in revised form 22 October 2015
Accepted 27 October 2015
Keywords:
Epilepsy
Perampanel
Antiepileptic drug
Responder rate
Tolerability
Efﬁcacy
A B S T R A C T
Purpose: To derive clinically useful information about the efﬁcacy and tolerability of adjunctive
treatment with perampanel for refractory epilepsy in an outpatient setting.
Method: We pooled retrospective casenotes data of adult patients with refractory epilepsy prescribed
perampanel from 18 hospitals throughout UK and Ireland.
Results: Three hundred and ten patients were included (mean age 40.9 [SD = 12.0], 50% women, 27.7%
with learning disability). The mean duration of epilepsy was 26.7 years (range 2–67 years, SD = 13.5) and
91.9% were taking two or more anti-epileptic drugs at the time of perampanel initiation. Mean retention
was 6.9 months (range 1 day–22.3 months, SD = 4.5). The retention was 86% at 3 months, 71% at
6 months, 47.6% at 12 months and 27% at 18 months. At ﬁnal follow-up a >50% reduction in seizure
frequency was reached in 57.5% of tonic–clonic seizures, 57.4% of complex partial seizures and 43.8% of
simple partial seizures. Eleven patients (3.5%) became seizure free. Two hundred and nine patients
(67.4%) experienced adverse effects and of these 67% withdrew treatment due to their effects. The most
common were sedation, behaviour/mood disturbance, dizziness, and unsteadiness.
Conclusion: Perampanel appears a safe and effective antiepileptic drug when used as adjunctive therapy
in patients with uncontrolled partial epilepsy (including those with learning disability), although few
patients achieved complete seizure control. Long-term retention was slightly lower than reported rates
for other anti-epileptic drugs, potentially due to the highly refractory population. Monitoring for adverse
effects on energy levels, mood and behaviour is recommended.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Perampanel is a new ﬁrst-in-class non-competitive AMPA
(a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) antag-
onist licensed as an adjunctive treatment for partial-onset seizures
in patients with refractory epilepsy aged twelve or above. It was
licensed for use in the UK in September 2012 and in the US in
October 2012.* Corresponding author. Present address: Developmental Neurosciences, Insti-
tute of Child Health, University College London, Guildford Street, London, WC1N
1EH, United Kingdom. Tel.: +44 020 7242 9789.
E-mail addresses: emily.shah@kcl.ac.uk, e.shah@ucl.ac.uk (E. Shah).
1 Present address: Academic Unit of Neuropsychiatry, King’s College London, St
Thomas’ Hospital, London, SE1 7EH, United Kingdom. Tel.: +44 020 7188 8059.
http://dx.doi.org/10.1016/j.seizure.2015.10.017
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reThree randomised, multi-centre, double-blind, placebo-con-
trolled trials of perampanel have demonstrated a major reduction
in seizure frequency at four different doses, with >50% responder
rates varying from 20.6% at 2 mg/day, 28.5% at 4 mg/day, 33.3–
37.6% at 8 mg/day and 33.9–36.1% at 12 mg/day. In these studies,
the placebo responder rates varied from 14.7 to 26.4% [1–3]. Two
post-marketing studies have been published, also showing high
response rate and good tolerability [4,5]. Here, we present the
clinical experience with perampanel in a large patient cohort from
ﬁfteen centres around the UK and Ireland.
2. Method
Data were obtained from case notes from eighteen secondary
and tertiary epilepsy centres in the UK and Ireland between
February 2014 and December 2014. Cases were identiﬁed from theserved.
Table 2
Impact of titration rate on patients without learning disability (LD).
2 mg/2 weeks >2 mg/2 weeks
No. of patients 131.0 22.0
Mean max dose (95%CI) 7.1 (6.9–7.7) 6.6 (5.5–6.9)
No. experienced AEs (%[CI]) 94.0 (75 [66.9–82.0]) 13.0 (61.9[40.8–79.3])
Sedation (%[CI]) 34.0 (27 [20.3–35.9]) 6.0 (30 [14.3–52.1])
Behavioural/mood
disturbance (%[CI])
26.0 (21 [14.7–29.0]) 3.0 (15 [4.1–35.5])
Unsteadiness (%[CI]) 21.0 (16.9 [11.3–24.6]) 1.0 (5 [<0.1–25.4])
Dizziness (%[CI]) 25.0 (20.1 [14.0–28.1]) 0.0
Mean length of treatment;
months (CI)
7.1 (6.3–7.4) 5.5 (4.1–5.9)
No. withdrew (%[CI]) 55.0 (42 [33.6–50.2]) 4.0 (18[6.7–39.1]
No. withdrew due to
adverse effects (%[CI])
37.0 (29.1 [22.0–37.6]) 3.0 (13.6 [3.9–34.2])
Seizure free 7.0 1.0
>50% reduction TCS at
ﬁnal FU (%[CI])
25.0 (56.8 [39.2–66.7]) 4.0 (50 [21.5–78.5])
>50% reduction CPS at
ﬁnal FU (%[CI])
39.0 (47 [36.6–57.6]) 4.0 (28.5 [1.5–12.1])
Table 1
Clinical features of all 310 patients that underwent perampanel treatment.
Characteristic Total number/number with
6 months FU
Age 18–30 74.0/33.0
31–50 166.0/87.0
51–75 70.0/41.0
Learning disability Yes 86.0/40.0
No 177.0/96.0
Gender Male 155.0/81.0
Female 155.0/80.0
Syndrome SPE/CPE 230.0/122.0
IGE 8.0/6.0
SGE 15.0/7.0
U 57.0/14.0
Concomitant AEDS 1 22.0/13.0
2 131.0/66.0
>3 154.0/80.0
Length of treatment (months) <3.0 60.0
3.0–5.9 87.0
6.0–8.9 71.0
9.0–11.9 47.0
>12.0 40.0
E. Shah et al. / Seizure 34 (2016) 1–52electronic medical and pharmacy records of patients who had been
prescribed perampanel. Those included were adults attending
their usual epilepsy clinic and the decision to use perampanel was
based upon the treating clinician’s recommendation. Data were
obtained by reviewing medical notes and clinic letters, then
entered on to an electronic database.
All adult patients who had been prescribed perampanel were
included, irrespective of the length of time they took the drug. The
only exclusion criterion was a lack of follow-up. Data included:
patient demographics, clinical features, history and treatment
details; such as concomitant antiepileptic drugs (AEDs), maximum
dosage of perampanel, length of exposure to perampanel, adverse
effects and withdrawal rates.
Patients were typically seen in clinic every three to six months.
Frequencies of seizures were obtained from medical notes or
seizure diaries when available. Clinicians usually documented the
number of seizures each month or provided a monthly average
since their previous review of the patient. If numerical recordings
of seizure frequency were not provided yet the clinician felt
improvement had been achieved, patients were recorded as
demonstrating a less than 50% reduction in seizure frequency.
Outcomes following treatment were deﬁned as follows:
 Seizure free: a terminal remission of seizures for three months or
more.
 50% or more reduction: a reduction in seizure frequency of 50% or
more in the last three months of follow-up compared with a pre-
treatment three month baseline. Only cases where seizure
frequency was accurately recorded were placed in this group.
 Less than 50% reduction: a reduction of between 1% and 49% in
seizure frequency in the last three months of follow-up
compared to the three month baseline period. A minority of
cases deemed to show improvement but lacking accurate
frequency data were also placed in this group.
 No reduction or worsening of seizures: this was based either on
numerically recorded frequencies or on qualitative clinical
impression.
Two response rates were determined, the ﬁrst based upon the
seizure frequency in the ﬁrst three months after commencing
perampanel and the second upon the three months prior to last
follow-up. Those with less than three months exposure were
excluded from the ﬁrst response rate. The second response rate
was only determined for patients with a minimum of six months
follow-up. Inferential statistical tests were used to describe the
dataset. Retention time on perampanel was estimated using
Kaplan–Meier survival curves and compared using a Tarone–Ware
test.
3. Results
Case notes were reviewed for 522 patients. A total of
310 patients (155 female) undergoing perampanel treatment
who had at least one follow-up were included in analysis.
230 patients were classiﬁed as having symptomatic or cryptogenic
partial epilepsy, 15 symptomatic generalised epilepsy, 8 idiopathic
generalised epilepsy and 57 patients were either unclassiﬁed or
their form of epilepsy was unknown. The following analyses were
ran separately for those patients with partial epilepsy, however, as
no differences were apparent between these patients and the
sample as whole, data for the overall cohort have been reported
here (Table 1).
Ages of the patients ranged between 18 and 75 years old (mean
40.9, SD = 12.0). The mean duration of epilepsy for this patient
group was 26.7 years (SD = 13.5) and mean number of concomitant
anti-epileptic drugs was 2.6 (range = 0–6, SD = 0.9). 91.9% of thesepatients were taking two or more AEDs at the time of perampanel
initiation.
3.1. Titration
The initial starting dose was typically 2.0 mg. This was then
titrated up by a further 2 mg/2 weeks in 64.2% of patients without
LD, although these increments varied between 2 mg/1 week and
2 mg/6 weeks according to the judgement of the clinician (Table 2).
The mean maximum dose reached was 7.1 mg (SD = 2.9), ranging
between 2 mg and 16 mg. Patients were divided into ‘fast’ (2 mg/
2 weeks) and ‘slow’ (>2 mg/2 weeks) titration groups. There was a
trend towards a signiﬁcant difference between the length of
treatment in the two titration groups; t(150) = 1.7, p = 0.090, 95%
CI [0.3,3.6]. Fisher’s exact test revealed a signiﬁcant difference in
the prevalence of dizziness in the fast and slow groups; p = 0.025.
3.2. Follow-up and outcome
The duration of perampanel treatment ranged from one day to
22.3 months with a mean of 6.9 months (SD = 4.5). The probability
of remaining on treatment with perampanel was assessed using
Fig. 1. Kaplan–Meier survival curve of perampanel retention times for all patients with partial onset epilepsy.
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perampanel treatment was 86.0% at three months, 71.0% at six
months, 47.6% at twelve months and 27.0% at eighteen months.
The ﬁrst outcome measure was taken at three months following
commencement of perampanel. Of the total 310 patients that were
initiated on the drug, 42 (13.5%) had already discontinued
treatment, predominantly due to adverse effects (AEs) (81.0%).
Twenty three patients were still on the treatment regime, but had
less than three months of exposure by the end of the study. This left
250 patients able to be included in analysis of the ﬁrst follow-up
(Table 3).
The second outcome was based upon seizure frequency during
the last three months of follow-up as compared to frequency
during the three month baseline period. One hundred and sixty one
patients were recorded with six months or longer duration of
treatment (Table 4). Of these, 45 had discontinued treatment
mostly due to lack of efﬁcacy (62.2%) or intolerable AEs (57.8%).
The mean duration of treatment at ﬁnal follow-up was 10.2 monthsTable 4
Seizure frequency responses during the three months before last follow-up.
Seizure type Patients with at least 6 months of follow up data, N (%[CI])
50% seizure reduction <50% seizure reductio
TCS (73.0) 42.0 (57.5 [46.1–68.2]) 3.0 (4.1 [0.9–11.9]) 
CPS (129.0) 74.0 (57.4 [48.7–65.6]) 14.0 (10.9 [6.5–17.5]) 
SPS (32.0) 14.0 (43.8 [28.2–60.7]) 5.0 (15.6 [6.4–32.2]) 
Table 3
Seizure frequency responses at three month follow-up.
Seizure type (N) Patients with at least 3 months of follow up data, N (%[C
50% seizure reduction <50% seizure reduct
TCS (77.0) 28.0 (36.4 [26.5–47.5]) 4.0 (5.2 [1.6–13.0])
CPS (101.0) 48.0 (47.5 [38.1–57.2]) 24.0 (24.2 [16.5–33.0
SPS (28.0) 11.0 (39.3 [23.5–57.6]) 8.0 (28.6 [15.1–47.2
Tonic–clonic seizures (TCS), complex partial seizures (CPS), simple partial seizures (SP(SD = 3.5). Nine patients (5.6%) were seizure free for a minimum of
three months at ﬁnal follow up.
3.3. Adverse effects
Adverse effects were experienced by 209 (67.4%) of all
310 patients (Table 5). The mean retention in these patients was
6.6 months (SD = 4.7). Of those 209 patients that experienced AEs,
83 (39.7%) withdrew perampanel predominantly due to intolerable
AEs, 26 (12.4%) withdrew due to lack of treatment efﬁcacy and
fourteen (6.7%) due to an increase in seizure frequency. In eleven
(5.3%) of these patients, the reason for withdrawal was not stated.
Amongst those 83 patients that withdrew treatment due to
intolerable side effects, fourteen also experienced a lack of efﬁcacy
and eight experienced increased seizure frequency.
The most common AEs experienced by patients were sedation
(23.8%), behavioural/mood disturbance (22.6%), dizziness (13.5%),
unsteadiness (11.3%) and increase in seizure frequency (7.1%).n No response Increase in seizure frequency
17.0 (23.3 [15.0–34.3]) 11.0 (15.1 [8.5–25.2])
26.0 (20.2 [14.1–28.0]) 15.0 (11.6 [7.1–18.4])
11.0 (34.4 [20.3–51.8]) 2.0 (6.3 [0.7–21.2])
I])
ion No response Increase in seizure frequency
 27.0 (35.1 [25.3–46.2]) 18.0 (23.4 [15.3–34.0])
]) 14.0 (13.9 [8.3–22.1]) 15.0 (14.9 [9.1–23.2])
]) 7.0 (25.0 [12.4–43.6]) 2.0 (7.1 [0.9–23.7])
S).
Table 5
Incidence and nature of adverse effects.
Adverse effect Number of patients (%)
Sedation 74.0 (23.8)
Behaviour/mood disturbance 70.0 (22.6)
Dizziness 42.0 (13.6)
Unsteadiness 35.0 (11.3)
Increase in seizure frequency 22.0 (7.1)
Weight change 16.0 (5.2)
Headache 13.0 (4.2)
Nausea 12.0 (3.9)
Sleep disturbance 9.0 (2.9)
Confusion/mental slowing 8.0 (2.6)
Double vision 7.0 (2.3)
Limb/Joint pain 7.0 (2.3)
Slurred speech 5.0 (1.6)
Gastrointestinal disturbance 5.0 (1.6)
Memory problems 4.0 (1.3)
Skin irritation 3.0 (1.0)
Depersonalisation 3.0 (1.0)
Breathlessness 3.0 (1.0)
Tremor 1.0 (0.3)
Hallucinations 1.0 (0.3)
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further, 18.1% of patients were found to have experienced
irritability/aggression and 7.7% experienced mood change/anxiety.
Four patients reported suicidal ideation; two of these patients
went on to attempt and one patient died by suicide.
3.4. Learning disability
Learning disability was present in 86 patients (27.7%), 47 of
whom were male. These patients had epilepsy for a mean of
27.4 years (SD = 10.6). They were taking a mean of 2.9 other AEDs
(SD = 1.0). Length of perampanel treatment for those with LD
ranged from 0.1 to 17 months (mean 6.3 months, SD = 4.0).
Patients with LD tended to be titrated up more slowly than those
without; 28.5% of those with LD increased their dose by 2 mg/3
weeks or longer whereas only 14.3% of patient without LD had the
same schedule.
A similar prevalence of AEs was recorded in patients with LD
(63.0%) as in those without LD (67.4%). The most commonly
reported AEs were behaviour/mood disturbance (29.1%), sedation
(23.3%) and dizziness (8.1%). The likelihood of discontinuing
treatment was similar for both groups (40.0% of those with
LD/39.5% of those without LD).
The probability of LD patients remaining on perampanel
treatment was 85.3% at three months, 69.6% at six months and
38.1% at twelve months (Fig. 1). A Tarone–Ware test was selected
due to the mildly crossing survival curves. This showed that there
was no difference between the survival curves for those with and
those without LD (p = 0.741).
In terms of efﬁcacy, perampanel appeared to be broadly similar
in patients with LD as without. Of those whom experienced
generalised seizures 42.3% had a 50% seizure reduction and 43.6%
of those with complex partial seizures experienced a 50%
reduction in seizure frequency. Given the difﬁculties in accurate
reporting of simple partial seizures in this patient group, data for
this seizure type have not been included. Two patients with LD
became completely seizure free.
3.5. Idiopathic generalised epilepsy
Eight patients in the sample had idiopathic generalised epilepsy
(three males). These patients had epilepsy for a mean of 28 years
(SD = 14.0) and were taking a mean of 2.9 concomitant AEDs
(SD = 1.0). The duration of perampanel treatment for this group ofpatients ranged from 2.0 to 11.1 months (SD = 3.3). No patients
withdrew from treatment, although one patient died due to SUDEP.
Two patients reported AEs, these being sedation and dizziness.
Two patients reported a 50% reduction in seizure frequency, four
reported <50% response, one patient did not respond to treatment
and one patient had an increase in seizure frequency.
4. Discussion
This study is reﬂective of the experience of perampanel
treatment in 310 patients with uncontrolled epilepsy. As data
were collated from eighteen outpatient centres (both secondary
and tertiary care) throughout the UK and Ireland, it provides a good
representation of the use of perampanel throughout these
countries, and is the largest observational study of perampanel
in a clinical setting to date. The sample of patients reported here
are a highly refractory group, as can be seen by the long durations
of epilepsy, high usage of concomitant AEDs and large proportion
of patients with LD. Given the highly refractory nature of many of
the patients included, this study also provided an opportunity to
review the effectiveness of perampanel for non-licensed indica-
tions. There was no major difference in efﬁcacy, tolerability or
safety in the partial-onset sub-group as opposed to the population
as a whole. Whilst more detailed investigation of these groups is
recommended, initial appearances suggest that perampanel may
be effective in groups broader than its licensed indications.
This study differs from other reports of perampanel in that
outcomes were assessed using retention time and that all adult
patients were included, regardless of seizure type. As this study
was a retrospective chart review, it was not always possible to
determine seizure frequency outcome from numerical data. Only
those with recorded frequency ﬁgures were included as >50%
responders; those felt by their clinicians to have shown qualitative
improvement were categorised with the <50% responders. It is also
possible that this study underestimates the adverse effects of
perampanel, however, as all patients were monitored by specialist
epilepsy services it is unlikely that major events were unrecorded.
Whilst these patients likely beneﬁtted from a close degree of
monitoring, it is a limitation of this study that all patients were
sourced from hospital-based clinics as this may restrict the
generalisability of ﬁndings from patients in different settings.
Although there are obvious difﬁculties in comparison of
retention rates between different drugs, the retention rates
reported here are broadly in keeping with those reported for
other new AEDs. Here, the one year retention rate was found to be
47.6%. The one-year retention rate for lacosamide is 68% [6], for
topiramate 60%, for lamotrigine 75% and for gabapentin 53%
[7]. There is, thus far, little long-term retention data available from
clinical samples for perampanel. However, marketing studies have
reported 38.4% remained on perampanel after 4 years [8], which
sits concordantly with long-term retention of other newer AEDs;
30% topiramate, 29% lamotrigine and <10% gabapentin [9].
Here, it was found that 67.4% of patients experienced AEs,
which lies between levels reported in both pooled analysis of the
three phase III studies (77%) [10] and the other clinical sample
(52.0%) [5]. It is likely that much of this discrepancy can be ascribed
to the differences between the prospective and retrospective
designs used. Data from the phase III trials describes how 12.4% of
those that experienced AEs withdrew perampanel treatment
because of this. The present study found this ﬁgure to be
considerably higher, with 39.7% of patients experiencing AEs
subsequently withdrawing treatment. The present study found
that the most common AEs reported were sedation (23.8%),
behaviour/mood disturbance (22.6%), dizziness (13.6%), and
unsteadiness (11.3%). It is difﬁcult directly to compare the
prevalence of individual AEs to those reported in the marketing
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reported at each dosage level, although the majority of the more
common AEs are the same. Certainly, looking at the clinical study,
levels of sedation (24.6%) and dizziness (19.6%) were very similar
to those reported here.
A notable exception to this is that considerably higher levels of
behaviour/mood disturbance were reported in this study than
others. Steinhoff’s [5] clinical study found aggression and
irritability in 4.9% of patients and a pooled analysis of phase III
studies reported aggression in just 1.6% [11], which stands in
contrast to the irritability/aggression reported in the present
sample (18.1%). Four patients in the study experience suicidal
ideation, with one patient later dying due to suicide; details of two
of these patients are available elsewhere in the literature
[12]. Limitations of retrospective design make it difﬁcult assess
reasons for the higher incidence of behaviour and mood related
AEs in this sample, nonetheless, it would seem appropriate to
monitor patients for neuropsychiatric AEs.
From comparing the impact of different titration rates on
patient experience, it would seem that by titrating up at a faster
rate patients were only slightly more likely to experience AEs,
however, they were considerably more likely to withdraw
treatment because of them. Whilst inferences can be drawn from
this are limited, a likely explanation would be that faster titration
increased the intensity of AEs.
There is little in the current literature regarding perampanel use
in those with LD, bar a case report concerning challenging
behaviour [13]. In the present sample, patients with LD were no
more likely to withdraw from perampanel treatment than those
without; the incidence of AEs was also broadly similar between the
two groups. There was no difference in the likelihood of remaining
of perampanel between those with and without LD. Thus, whilst
further investigation within this sub-population would be beneﬁ-
cial, initial appearances are that perampanel is well tolerated in
those with LD.
5. Conclusion
Adjunctive therapy with perampanel appears to be well-
tolerated and effective for treating partial and generalised seizures
in patients with difﬁcult-to-treat epilepsy. Long-term retention
rates were slightly lower than reported rates for other AEDs,
although this may be partially explained by the highly refractory
nature of this study’s population. It seems similarly safe and
effective in the subgroup of these patients with LD. Monitoring
for adverse effects on energy levels, mood and behaviour is
recommended.
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